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ABSTRACT
Graft-versus-host disease (GVHD) is the principal complication after allogeneic bone marrow transplantation
(BMT). Reductions in systemic GVHD are frequently associated with a corresponding diminishment of the
graft-versus-leukemia (GVL) response. In this study, we tested the effects of a novel recombinant human
keratinocyte growth factor, repifermin (keratinocyte growth factor-2), on the induction of GVHD in a
well-defined murine BMT model (B6 3 B6D2F1). Administration of repifermin (5 mg/kg/d) to allogeneic
BMT recipients resulted in a significant decrease in both systemic GVHD and target organ histopathology.
Repifermin treatment also reduced serum levels of tumor necrosis factor  and lipopolysaccharide compared
with control mice. In contrast, repifermin did not affect T-cell proliferation, cytokine production, or cytotoxic
responses to host antigens. When 2000 host-derived P815 (H-2d) leukemia cells were added to the bone
marrow inoculum, repifermin preserved GVL effects and resulted in significantly delayed mortality compared
with control-treated allogeneic BMT recipients. Collectively, these data suggest that repifermin administra-
tion may represent a novel strategy to separate the toxicity of GVHD from the beneficial GVL effects after
allogeneic BMT.
© 2003 American Society for Blood and Marrow Transplantation
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Allogeneic bone marrow transplantation (BMT) is
n important therapy for a number of hematologic
alignancies. The therapeutic potential of BMT is
ue to a graft-versus-leukemia (GVL) effect that is
rincipally driven by donor T and natural killer cells
resent in the stem cell graft [1]. Unfortunately, the
tility of allogeneic BMT is limited by several adverse
omplications, including graft-versus-host disease
GVHD). GVHD results in direct damage to the
astrointestinal (GI) tract, liver, skin, and lungs
hrough cellular and cytokine-mediated effectors and (
92an lead to death of the recipient [2]. Strategies that
ffectively separate the beneﬁcial GVL effects from
he toxicity of GVHD are necessary for enhanced
urvival after BMT. Reductions in systemic GVHD
an be achieved through depletion of donor T cells in
he graft, but not without a corresponding decrease in
he GVL response [3]. An alternative strategy is to
aintain donor T-cell function but reduce acute
VHD by disrupting the generation of inﬂammatory
ytokines known to damage the sensitive epithelial
ucosa of the gut [4]. Recent studies have shown that
oss of GI integrity and subsequent lipopolysaccharideoi:10.1016/S1083-8791(03)00230-1e
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lcLPS) translocation into the systemic circulation con-
tributes to the cytokine dysregulation and ampliﬁca-
tion of the GVH reaction [5,6].
The ﬁbroblast growth factor (FGF)-10 [7,8] pro-
tein product, repifermin (Human Genome Sciences,
Inc., Rockville, MD), is a genomics-derived, truncated
form of keratinocyte growth factor-2 (KGF-2). Repi-
fermin, like KGF-1 (FGF-7), stimulates proliferation,
differentiation, and migration of epithelial cells [9-11].
The gene encoding repifermin, FGF-10, has been
shown to be important in the embryogenesis and de-
velopment of a diverse number of tissues, including
lung [12,13], liver [14], limbs [13,15-17], thymus [18],
kidney [19], lacrimal gland [20,21], teeth [22,23],
prostate [24,25], adipose tissue [26,27], and stomach
[28]. Repifermin also plays a role in the development
of adult epithelial tissue, including the lung and epi-
dermis [7]. Because of its epithelial speciﬁcity, repi-
fermin offers the potential to treat many conditions
requiring repair and regeneration of epithelium, in-
cluding incisional wounds [10,29], chronic cutaneous
ulceration [30], chemotherapy-induced mucositis [31],
and ulcerative colitis [32]. Like KGF-1, repifermin
induces mucosal thickening in normal tissue [33] and
speeds the healing of injured intestinal mucosa, an
effect that may be particularly relevant to GVHD
management [6].
Given the primacy of the GI tract in amplifying
the GVH reaction, coupled with the presumed ther-
apeutic action of repifermin, we chose to investigate
this drug in a well-established mouse BMT model.
Neither repifermin [34,35] nor KGF-1 [36,37] ap-
pears to be highly immunogenic, and KGF receptors
have not been described on hematopoietic cells; there-
fore, these molecules are not likely to be directly
immunosuppressive. We hypothesized that repifermin
treatment would preserve intestinal barrier function
and limit endotoxin secretion into the circulation, thus
reducing the systemic inﬂammation and severity of
GVHD while not appreciably altering donor T-cell
function, thereby preserving beneﬁcial GVL effects.
MATERIALS AND METHODS
Transplant Details
The BMT procedures used in this study have been
previously reported [38]. Brieﬂy, female B6D2F1 mice
(H-2bxd, CD45.2) were purchased from the Freder-
ick Cancer Research and Development Center (Na-
tional Cancer Institute, Frederick, MD) or Jackson
Laboratories (Bar Harbor, ME) and underwent trans-
plantation at 12 weeks of age with bone marrow (BM)
and T cells from 10-week-old syngeneic B6D2F1
mice or allogeneic C57BL/6 (B6) mice (H-2b,
CD45.1) obtained from the National Cancer Insti-
tute. Host mice were conditioned with 1500 cGy of
total body irradiation (TBI). TBI was delivered by
using a 137Cs source Gamma Cell 40 Model C-161
Type 8 irradiator (Nordion International, Inc., On-
tario, Canada) delivered in 2 equal doses (at 92-94
cGy/min) separated by 3 hours to reduce GI toxicity.
A conditioning regimen of 1500 cGy TBI was chosen
so that these experiments could be directly compared
with previous studies that used this regimen and to
maximize GI pathology so that the potential effects of
repifermin could be clearly observed. Marrow was
harvested from the femurs and tibias of the donor
mice. Mixtures of 5.0  106 BM cells were supple-
mented with 0.5 106 nylon wool puriﬁed nonadher-
ent splenic T cells and resuspended in Leibovitz L-15
serum-free medium (Gibco Life Technologies, Grand
Island, NY) and transplanted on day 0 into condi-
tioned recipients via intravenous tail vein injection
(0.25 mL). Under these conditions, our mice succumb
3 or 4 days after TBI unless rescued with BM cells, as
has been observed in other high-intensity irradiation
settings [39]. Mice were subsequently housed in sterile
microisolator cages, fed normal chow and autoclaved,
acidiﬁed water for the ﬁrst 3 weeks after BMT, and
given ﬁltered water thereafter. All experiments involv-
ing mice were conducted in accordance with standard
operating procedures approved by the University
Committee on the Use and Care of Animals.
Repifermin Administration
Recombinant human repifermin was supplied by
Human Genome Sciences, Inc. Repifermin was re-
constituted in double-distilled 0.45 M ﬁltered water
and diluted in carrier buffer (7% sucrose, 10 mM
sodium citrate, 20 mM NaCl, and 1 mM EDTA;
Human Genome Sciences, Inc.) just before injection.
Care was taken to maintain reconstituted repifermin
at 4°C and to avoid shear forces and evaporative ef-
fects while injecting. Previous clinical studies have
demonstrated that repifermin is well tolerated
through a variety of administration routes, including
intravenous, intraperitoneal (IP), and subcutaneous
[40]. For our initial experiments, mice were injected
IP with 5 mg/kg daily from day 3 to day 7. This
dosing schedule has been shown to be effective in a
number of murine investigations for both KGF-1
[41,42] and for repifermin [32,40]. In subsequent ex-
periments, the repifermin dosing scheme was modi-
ﬁed to either 24 consecutive days (from day 3 to day
21) or to 45 days administered for 3 days followed by
4 days without injection (from day 3 to day 42).
We also investigated 10 and 20 mg/kg with this longer
administration course. All control mice received di-
luent-only IP injections.
GVHD Evaluations and Analyses
The severity of GVHD was determined by using a
clinical scoring system previously described that in-
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corporates 5 parameters: weight loss, activity, posture,
fur texture, and skin condition [43]. This scoring sys-
tem is a more sensitive indicator of GVHD severity
than weight loss alone. Recipient mice were ear-
punched, and individual parameters were measured on
day 1, day 7, and weekly thereafter. Changes were
graded from 0 to 2 for each parameter to generate a
clinical index with a maximum score of 10. Under the
speciﬁc transplant conditions of this study, severe
GVHD (often leading to death) was evident when
clinical scores reached 6 or higher.
Tissue Harvest and Histologic Examination
At various time points, mice were killed by CO2
asphyxiation followed by bilateral pneumothorax in-
duction, and GVHD target organs were harvested.
Small- and large-intestine and liver samples were col-
lected and preserved in formalin for 24 to 48 hours
and then transferred to 70% ethanol for storage be-
fore embedding. Preserved specimens were embedded
in parafﬁn, cut into 5-m-thick sections, and stained
with hematoxylin and eosin for histologic examina-
tion. Slides were systematically examined in a blinded
fashion by a single researcher (C.L.) without regard
for mouse condition or treatment regimen by using an
index of injury that has been previously published [44].
Evaluation of the intestine included the following his-
tologic changes that are known to be associated with
GVHD: villous blunting, epithelial cell apoptosis,
crypt regeneration, neutrophilic inﬁltrate, mucosal ul-
ceration, lamina propria inﬁltration and luminal
sloughing of the small bowel; epithelial cell apoptosis;
crypt regeneration; neutrophilic inﬁltrate; epithelial
attenuation; and lamina propria inﬂammatory cell in-
ﬁltration in the large bowel. A similar scoring system
was used for liver injury and graded changes in the
following: portal tract expansion, mononuclear cell
inﬁltration of the portal tracts, nuclear pleomorphism
of the bile ducts, vascular endothelialitis, and hepato-
cellular changes, including mitotic ﬁgures, conﬂuent
necrosis, acidophilic bodies, foamy changes, neutro-
phil accumulations, and macrophage aggregates. Scor-
ing was as follows: 0 (normal), 0.5 (focal/rare), 1.0
(focal/mild), 2.0 (diffuse/mild), 3.0 (diffuse/moderate),
or 4.0 (diffuse/severe). Individual parameters were
summed for each tissue to arrive at a composite score.
Composite scores for small bowel, large bowel, and
liver were compared from syngeneic control-treated,
allogeneic control-treated, and allogeneic repifermin-
treated mice to assess relative degrees of tissue dam-
age.
Cell Culture Techniques
Cells were cultured as previously described
[38,44]. Splenocytes were harvested from transplant
recipients on day 13, the time of peak T-cell expan-
sion in this model, and 3 to 5 spleens were pooled.
Mononuclear cells were recovered via Ficoll (Amer-
sham, Piscataway, NJ) gradient centrifugation as pre-
viously described [44]. The percentages of CD4 and
CD8 T cells were normalized via ﬂow cytometric
analysis and plated at a concentration of 105 total
CD4 and CD8 T cells per well with 105 irradiated
(2000 cGy) peritoneal macrophages lavaged from
naı¨ve B6D2F1 or B6 mice, respectively. After 40 hours
of incubation, the mixed lymphocyte reactions were
pulsed with 1 Ci per well of [3H]thymidine, and
proliferation was assessed 24 hours later with a Top
Count microscintillation and luminescence counter
(Packard Instruments, Downers Grove, IL). Cytotoxic
T lymphocyte (CTL) assays were performed accord-
ing to previously published methods for chromium 51
(51Cr) release [44] by using the identical T-cell pop-
ulations used for the aforementioned mixed lympho-
cyte reactions. The P815 (H-2d) mouse mastocytoma
cell line was cultured in RPMI media supplemented
with 10% fetal bovine serum at 37°C and 5.0% CO2.
This cell line was used both as targets in the CTL
assay and for in vivo GVL experiments. The percent-
age of speciﬁc lysis was calculated accordingly by sub-
tracting spontaneous 51Cr release from experimental
51Cr release and dividing this product by the total
51Cr release minus spontaneous release [44,45]. Tar-
get cells cultured in media alone were used to deter-
mine spontaneous 51Cr release. Total release was de-
termined by lysing target cells with Triton X.
Endotoxin Determinations
Concentrations of LPS were measured in serum
by the limulus amebocyte lysate (LAL) assay (Bio-
Whittaker, Walkersville, MD) according to the man-
ufacturer’s protocol. Brieﬂy, serum samples were col-
lected and analyzed with pyrogen-free materials.
Samples were diluted 1:10 or 1:20 in LAL reagent
water and heated at 70°C for 5 minutes to minimize
nonspeciﬁc inhibition. Samples were then incubated
with an equal volume of LAL for 10 minutes at 37°C.
Samples were developed with an equal volume of
substrate solution for 6 minutes at 37°C. The absor-
bance of the assay plate was read at 405 nm by using
a Spectramax 190 plate reader (Molecular Devices
Corporation, Sunnyvale, CA). The lower limit of de-
tection in each LAL experiment was less than 0.063
U/mL for each assay. In all LAL determinations, stan-
dards were run in triplicate and samples in duplicate.
Fluorescence-Activated Cell Sorting
Determinations
Fluorescein isothiocyanate (FITC)–conjugated
anti-mouse CD4, CD45.1, and CD45.2 and phyco-
erythrin (PE)–conjugated anti-mouse CD8 monoclo-
nal antibodies (MoAbs) were purchased from BD
S. G. Clouthier et al.
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Pharmingen (San Diego, CA). Cells were ﬁrst washed
free of media by using a phosphate-buffered saline
(PBS) containing 0.2% bovine serum albumin and
then incubated at 4°C in FITC anti-mouse CD16/
CD32 (Fc III/II; 2.4G2) MoAbs for 15 minutes to
limit nonspeciﬁc binding via Fc receptors. Subsequent
incubation with FITC or PE-conjugated antibody oc-
curred at 4°C for 30 minutes. Labeled cells were then
washed twice in PBS containing 0.2% bovine serum
albumin and ﬁxed with PBS containing 1.0% parafor-
maldehyde. Two-color ﬂow cytometric analyses were
conducted by using either an EPICS Elite ESP cell
sorter (Beckman Coulter, Miami, FL) or a FACS
Vantage SE cell sorter (Becton Dickinson, San Jose,
CA). Flow cytometry instrumentation was calibrated
by using FITC- and PE-conjugated nonspeciﬁc im-
munoglobulin G antibodies. In GVL experiments,
FITC anti-mouse H-2d (Cedarlane Labs, Ontario,
Canada) and PE anti-mouse H-2b (BD Pharmingen)
MoAbs were used to assess leukemic burden at the
time of death. Cells were stained as previously de-
scribed [44]. Donor cell engraftment was determined
by analyzing the percentage of CD45.1 and
CD45.2 cells in spleen and/or peripheral blood on
day 56 or day 81 after transplantation. Isotype control
staining was performed for each ﬂuorescence-acti-
vated cell sorting (FACS) analysis.
Cytokine Determinations
Concentrations of tumor necrosis factor 
(TNF), interferon  (INF), and interleukin-2
(IL-2) were measured in sera or supernatant by en-
zyme-linked immunosorbent assay by using speciﬁc
anti-murine MoAbs for capture and detection. The
TNF Quantikine kits (including the appropriate
standards) were purchased from R &D Systems (Min-
neapolis, MN), and the INF and IL-2 OptEIA kits
were purchased from BD Pharmingen. Assays were
performed according to the manufacturer’s protocol.
Brieﬂy, samples were diluted 1:2 to 1:4, and TNF,
INF, or IL-2 was captured by using the speciﬁc
primary MoAb and detected with horseradish perox-
idase-conjugated secondary MoAb. Plates were read at
450 nm by using a Spectramax 190 plate reader (Mo-
lecular Devices Corporation). Recombinant mTNF,
mINF, and mIL-2 were used as standards. The lower
limits of detection in these assays were 5.1 pg/mL for
TNF, 15.3 pg/mL for INF, and 4.0 pg/mL for
IL-2. All enzyme-linked immunosorbent assay deter-
minations for samples and standards were prepared in
duplicate and averaged.
GVL Analyses
In GVL experiments, mice received BM that was
depleted of T cells by negative selection by using an
AutoMACS (Miltenyi Biotec, Auburn, CA) column
with beads coated with anti-mouse CD90 (Thy1.2). At
the time of marrow infusion, 2000 P815 (American
Type Culture Collection, Rockville, MD) mouse mas-
tocytoma tumor cells (syngeneic to the host) were
given. Injection of 2000 P815 cells results in 100%
mortality of BMT T cell–depleted (TCD) recipients
in the ﬁrst 2 to 3 weeks after transplantation [46].
Mice were monitored closely each day, and necropsies
were performed at the time of death to collect tissues
for FACS analysis and histologic evaluation to deter-
mine whether residual tumor was present. The sensi-
tivity of this FACS analysis to identify P815 tumor
cells was 0.1%. Some mice received 0.5  106 nylon
wool puriﬁed splenic donor T cells to induce GVHD.
The cause of death was determined to be GVHD if
the mice lacked observable tumor cells in target tissues
and had a paucity of H-2d cells in the spleen and/or
liver in association with increased clinical GVHD
scores and splenic atrophy. Mouse deaths were attrib-
uted to leukemia when macroscopically or histologi-
cally observable tumor cells were found in target tis-
sues or were observed by FACS analysis (eg, 0.1%
H-2kdb cells).
Statistical Interpretations
All cellular assay and pathology data are expressed
as mean SD, and all clinical data are expressed as the
mean  SEM unless otherwise indicated. Statistical
comparisons between groups were completed by using
the nonparametric unpaired Mann-Whitney test for
in vitro data, clinical scores, and histology scores (P 	
.05 was considered signiﬁcant). Survival curves were
plotting by using Kaplan-Meier estimates and com-
pared with the Mantel-Cox log-rank test.
RESULTS
Repifermin Decreases GVHD in the Intestine and
Liver while Reducing TNF and LPS Levels after
Allogeneic BMT
We hypothesized that administration of repifer-
min would reduce acute GVHD severity in the gut
after allogeneic BMT because of the reparative effects
that repifermin has on the GI mucosa. We tested this
hypothesis by using the well-characterized B6 3
B6D2F1 mouse BMT model, wherein GVHD is in-
duced by both major histocompatibility complex
(MHC) and minor histocompatibility antigen (MiHA)
differences between donor and host. B6D2F1 mice
received lethal irradiation (1500 cGy, split dose), fol-
lowed by the infusion of BM and splenic T cells from
either syngeneic (B6D2F1) or allogeneic (B6) donors.
Allogeneic BMT recipients were given repifermin (5
mg/kg/d) or control diluent from day 3 to day 7,
and syngeneic mice were given control diluent only.
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Small-bowel samples were harvested from both syn-
geneic and allogeneic recipients on day 7 after BMT.
Specimens obtained from syngeneic mice demonstrated
re-establishment of near-normal intestinal histology
(Figure 1A). In contrast, allogeneic BMT resulted in
severe damage to the GI tract that included prominent
villous blunting, moderate epithelial apoptosis, and a
pronounced lymphocytic inﬁltrate (Figure 1B). Repi-
fermin administration signiﬁcantly reduced architec-
tural destruction and cellular inﬂammation and re-
sulted in an increased abundance of mucin-secreting
cells in the small bowel in comparison to allogeneic
control mice. Repifermin-treated mice demonstrated
intact intestinal villi, crypt regeneration, and a re-
duced cellular inﬁltrate in comparison to allogeneic
control-treated mice (Figure 1C). A semiquantitative
analysis of the severity and extent of GI tract injury
showed that repifermin administration decreased the
overall histology score after allogeneic BMT in the
small bowel compared with controls (Table 1; P 	
.001). Differences between groups were also noted for
the large bowel, where this effect persisted as late as
day 48 after BMT (Table 1).
We next evaluated the effect of repifermin on
hepatic GVHD. Liver samples taken 7 days after syn-
geneic BMT were histologically normal (Table 1),
whereas livers from allogeneic controls were histolog-
ically abnormal, with evidence of portal tract expan-
sion, mononuclear inﬁltration of the portal triads,
vascular endothelialitis, and hepatocellular damage
(acidophilic bodies, neutrophil accumulations, and
foamy changes). These ﬁndings were incorporated
into a semiquantitative scoring system [47]. Adminis-
tration of repifermin resulted in signiﬁcantly reduced
damage to the liver 7 days after BMT, particularly
with regard to the degree of mononuclear cell inﬁl-
tration surrounding the portal triads and the number
of acidophilic bodies (Table 1; P 	 .001). The prev-
alence of mitotic ﬁgures observed early and only in the
livers of repifermin-treated mice suggested a prolifer-
ative effect of this drug on hepatocytes. In contrast to
pathologic changes seen in the intestine, damage to
Figure 1. Effects of repifermin on histologic and biochemical markers of GVHD. Recipient mice (B6D2F1) underwent transplantation with
5  106 bone marrow cells and 0.5  106 T cells from syngeneic (B6D2F1) or allogeneic (B6) mice after conditioning with 1500 cGy of TBI
administered via split dose. Repifermin (5 mg/kg) or control diluent was given intraperitoneally once daily from day3 to day7. Small-bowel
samples were taken for histology 7 days after BMT from (A) syngeneic BMT controls, (B) allogeneic BMT controls, and (C) allogeneic BMT-
and repifermin-treated cohorts. Pathologic features were scored in a blinded fashion (by C.L.) and summed as described in Materials and
Methods. Allogeneic BMT control mouse bowel exhibited severe disruption of the intestinal architecture, including villous blunting,
lymphocytic inﬁltration, and signiﬁcant crypt destruction. Serum LPS (D)  syngeneic, n 
 8; f allogeneic, n 
 22; allogeneic 
repifermin, n 
 21) and TNF (E) ( syngeneic, n 
 8; f allogeneic, n 
 22; allogeneic  repifermin, n 
 17) were measured 7 days after
BMT in syngeneic and allogeneic recipient mice treated with either repifermin (5 mg/kg/d from day 3 to day 7) or diluent only f versus
, *P 
 .03).
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the liver caused by GVHD continued to intensify
between days 7 and 48. Repifermin administration did
not protect the liver against these later changes, which
could reﬂect either the kinetics of damage or some
degree of target organ speciﬁcity. Further experiments
are needed to clarify this issue.
Damage to the gut mucosa has been shown to be
associated with LPS (endotoxin) leakage into the sys-
temic circulation [38]. LPS is a potent trigger for the
release of inﬂammatory cytokines such as TNF, the
secretion of which is thought to further exacerbate GI
damage during GVHD. We therefore examined se-
rum LPS and TNF levels 7 days after BMT, a time
when signiﬁcant histologic GI damage from GVHD
was observed in allogeneic BMT recipient mice. We
found that LPS levels in repifermin-treated mice were
signiﬁcantly less (P 
 .03) than allogeneic control-
treated recipients, albeit higher than syngeneic BMT
controls (Figure 1D). Serum TNF levels on day 7
after BMT were similarly reduced in repifermin-
treated mice (Figure 1E; P 
 .03).
Repifermin Treatment Reduces the Mortality and
Morbidity of GVHD
Given the protective effects of repifermin on the
GI tract and the subsequent reduction in serum LPS
and TNF levels, we hypothesized that repifermin
administration would attenuate the severity of sys-
temic GVHD. As shown in Figure 2A, the adminis-
tration of repifermin from day 3 to day 7 signiﬁ-
cantly reduced GVHD-associated mortality; by day 42
after allogeneic BMT, only 18% of the control-
treated mice were alive, whereas 67% of the repifer-
min-treated mice had survived (P 	 .01). We also
evaluated the severity of GVHD in surviving mice by
using a clinical scoring system, as previously described
[48]. Mice treated with repifermin had signiﬁcantly
less clinical GVHD compared with control-treated
mice in the ﬁrst month after BMT and lost less of
their initial body weight compared with control mice.
Scores, however, did not return to baseline, demon-
strating that GVHD had not been completely pre-
Table 1. Intestinal and Liver Histopathology after BMT*
Specimen Syngeneic  Control Allogeneic  Control Allogeneic  Repifermin
Day 7 n  6 n  12 n  7
Small bowel 3.3  0.8 8.8  0.4 3.1  0.5†
Large bowel 4.3  1.1‡ 8.3  0.5 2.4  0.3†
Total bowel score 7.6  1.9 17.1  0.9 5.6  0.8†
Liver 0.2  0.2 5.6  0.4 1.4  0.3†
Day 48 n  3 n  3 n  3
Small bowel 2.5  1.2 5.7  0.3 4.3  0.3§
Large bowel 0.0  0.0 6.0  1.0 3.3  0.7‡
Total bowel score 2.5  1.2 11.7  1.3 7.6  1.0‡
Liver 0.5  0.5 9.0  1.7 13.7  1.8
*Histopathology scores for small-bowel, large-bowel, and liver samples taken 7 or 48 days after BMT after 1500-cGy conditioning. Transplant
conditions and the histopathology scoring system are fully described in Materials and Methods. Repifermin (5 mg/kg) or diluent (control
mice) was administered from day 3 to day 7. All data are reported as mean  SEM. Allogeneic small-bowel, large-bowel, total-bowel and
liver scores from mice treated with repifermin showed improved histopathologic scores when compared with allogeneic control-treated mice
(†P 	 .001, ‡P 
 .04, §P 
 .02) for all comparisons except day 48 liver histopathology. Additionally, repifermin-treated large-bowel samples
were statistically different from those of syngeneic control-treated mice (‡P 	 .04).
Figure 2. Repifermin enhances post-BMT survival and reduces
GVHD after allogeneic BMT. Mice underwent transplantation as
in Figure 1. Repifermin (5 mg/kg) or control diluent was given
intraperitoneally daily from day 3 to 7 as shown by the bar on
the x axis. A, Survival estimates are shown by Kaplan-Meier cumu-
lative curves obtained by combining results for 2 similar experi-
ments (f syngeneic, n 
 10; F allogeneic, n 
 22; ‚ allogeneic 
repifermin, n 
 17). B, The clinical GVHD scores (f syngeneic,
n 
 10; F allogeneic, n 
 22; ‚ allogeneic  repifermin, n 
 17)
for all mice were determined by summing 5 parameters as described
in Materials and Methods and plotted as mean  SEM. *P 	 .01.
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vented by repifermin. Analysis of CD45.1 alleles on
spleen and peripheral blood on day 56 indicated that
complete donor hematopoietic engraftment was
achieved (data not shown), thus excluding mixed chi-
merism as a potential explanation for the reduction in
GVHD.
Extended Treatment Regimen and Dose
Escalation of Repifermin Does Not Provide
Additional Benefit after Allogeneic BMT
We next evaluated whether longer administration
or increased doses of repifermin might further reduce
acute GVHD. When repifermin was administered IP
for 3 consecutive days per week for 6 weeks after
BMT, mortality and morbidity were similar to those
observed when repifermin treatment stopped at day
10 (Figure 3A and 3B). Administration of repifermin
IP for 24 consecutive days (from day 3 to day 21)
also did not further reduce GVHDmortality (data not
shown). Administration of higher doses (10 and 20
mg/kg) 3 days per week for 6 weeks after BMT (day
3 to 42) did not further reduce GVHD mortality
(day 90 survival: 50% and 63%, respectively, versus
56% for a 5 mg/kg dose).
Repifermin Preserves Donor T-Cell Function
The induction of acute GVHD fundamentally de-
pends on alloreactive T cells present in the donor
graft [49], and we therefore investigated the effects of
repifermin on donor T-cell responses. As shown in
Table 2, early after BMT, there were no appreciable
differences between repifermin and the control-
treated allogeneic group in terms of serum INF lev-
els (day 6) or donor CD4/CD8 T-cell expansion
(day 13). Next we evaluated in vitro splenic T-cell
function. T cells were harvested on day 13 after BMT,
and equal numbers of CD4 and CD8 cells were
re-stimulated with either irradiated host-type antigen-
presenting cells (APCs) or P815 (H-2d) tumor targets.
Repifermin administration had no effect on T-cell
proliferation, IL-2 production, or CTL generation
(Table 3; Figure 4).
Repifermin Preserves GVL after Allogeneic BMT
Because repifermin administration preserved do-
nor T-cell responses after allogeneic BMT, we hy-
pothesized that repifermin would also preserve GVL
activity in this setting. To test this hypothesis, 2000
Figure 3. Effects of 6-week administration of repifermin after
BMT. Recipient mice underwent transplantation as in Figure 1.
Repifermin (5 mg/kg) or control diluent was given from day 3 to
day 42 as denoted by the bold portion of the x axis. A, Survival
estimates are shown by Kaplan-Meier cumulative curves obtained
by combining results for 2 similar experiments (f syngeneic, n 

12; F allogeneic, n 
 16; ‚ allogeneic  repifermin [5 mg/kg], n 

16. B, The clinical GVHD scores expressed as mean  SEM (f
syngeneic, n 
12; F allogeneic, n 
16; ‚ allogeneic  repifermin
[5 mg/kg], n 
 16) for all mice are reported as before. *P 	 .001.
Table 2. Splenic T-Cell Counts and Serum Cytokine Levels*
Splenic T-Cell Number (106)
INF Serum Level
(pg/mL)Group CD4 CD8 Total
Syngeneic  diluent 1.8  0.6 1.4  0.6 3.2  1.2 133  18
Allogeneic  diluent 4.1  1.2 7.1  1.7 11.2  2.9 3315  1178
Allogeneic  repifermin 5.3  2.0 8.5  2.0 13.8  4.0 3491  499
*Splenic T-cell expansion 13 days after BMT and systemic INF production obtained from sera samples obtained 6 days after BMT. B6D2F1
mice received either a syngeneic or allogeneic BMT with or without repifermin (5 mg/kg) as described in Materials andMethods. Repifermin
administration did not appreciably alter CD4 or CD8 T-cell expansion in the spleen, nor did it affect systemic INF production after
allogeneic BMT. T-cell numbers were quantiﬁed by FACS, and INF levels were determined by enzyme-linked immunosorbent assay as
described in Materials and Methods. Data represent mean  SD for 9 to 12 mice per group obtained from 3 similar experiments.
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host-type (H-2d) P815 tumor cells were added to the
BM inoculum on the day of transplantation. B6D2F1
recipient mice were conditioned with 1500 cGy of
TBI followed by the infusion of TCD allogeneic (B6)
BM either alone or with 0.5  106 splenic T cells.
Allogeneic BMT recipients received either repifermin
(5 mg/kg) or control diluent from day 3 to day 7.
As shown in Figure 5, injection of 2000 P815 cells
resulted in complete mortality of recipients of TCD
BM by day 21. These mice had gross macroscopic
evidence of tumor inﬁltration and massive hepato-
splenomegaly on necropsy after day 14. Treatment of
TCD BMT recipients with repifermin had no effect
on survival. In contrast, allogeneic BMT recipients
treated with repifermin demonstrated a signiﬁcant
GVL effect but succumbed rapidly to GVHD. Evidence
of leukemia burden was assessed in mice at the time of
death by FACS analysis and histologic evaluation of the
spleens and livers, as described in Materials and Meth-
ods. A minority of mice showed evidence of leukemia in
both control and repifermin-treated groups (4/13 versus
2/9, respectively), whereas repifermin-treated mice
showed a signiﬁcantly delayed mortality (Figure 5; P 

.04). These data demonstrate that repifermin preserves a
GVL effect while delaying the onset of GVHD after
allogeneic BMT. Furthermore, repifermin in and of it-
self does not appear to have any effects on tumor growth
in this model, a ﬁnding that is consistent with other
KGF tumor studies [50,51].
DISCUSSION
We have demonstrated that repifermin adminis-
tration reduces the severity of GVHD after allogeneic
Table 3. Splenocyte Function after BMT*
Proliferation on Day 13 (103 cpm) IL-2 on Day 13 (pg/mL)
Group
B6D2F1
Stimulators
B6
Stimulators
B6D2F1
Stimulators
B6
Stimulators
Allogeneic  diluent 15.5  1.6 1.7  1.1 76.6  16.9 3.6  1.8
Allogeneic  repifermin 18.6  1.9 2.4  1.8 71.0  5.8 2.7  2.2
*Cellular proliferation and cytokine production of recipient splenocytes obtained from harvest supernatants 13 days after BMT after repriming
with donor and host-type peritoneal macrophage stimulators. B6D2F1 recipient mice received an allogeneic BMT with or without a course
of repifermin (5 mg/kg from day 3 to 7) as described in Materials and Methods. Proliferation and IL-2 secretion were determined by
mixed lymphocyte reaction and enzyme-linked immunosorbent assay, respectively, as described in Materials and Methods. Data represent
mean  SD for triplicate wells obtained from 3 separate experiments.
Figure 4. Repifermin effects on CTL activity after BMT. Mice underwent transplantation as in Figure 1 and received either diluent or
repifermin from day 3 to 7. On day 13 after BMT, mouse splenocytes were used as effectors in a CTL assay as described in Materials
and Methods. Splenocytes were pooled from 3 to 5 mice per group. Data represent mean  SD from 1 of 3 similar experiments.
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BMT by fostering gut mucosal regeneration and re-
ducing systemic levels of LPS and TNF. We have
also shown that repifermin administration does not
appreciably alter donor T-cell responses to host anti-
gens either in vivo (serum INF and T-cell expansion)
or in vitro (T-cell proliferation and IL-2 secretion).
Cytotoxic T-cell function is similarly unaltered in
mice treated with repifermin, a ﬁnding that was asso-
ciated with the preservation of GVL effects after
BMT. These data corroborate and expand the thera-
peutic potential of a growing list of epithelial growth
factors, including epidermal growth factor (EGF),
hepatocyte growth factor (HGF), and KGF-1, in the
prevention of inﬂammatory bowel damage and asso-
ciated inﬂammatory disorders, including acute
GVHD.
Investigations into the pathophysiology of acute
GVHD have revealed that the integrity of the GI tract
is critical to limit the progression of systemic disease
[5,52]. Speciﬁcally, these studies have highlighted a
central role for LPS and TNF during the early stages
of inﬂammation that culminate in GVHD. Novel
strategies to prevent acute GVHD now include LPS
antagonism [5], cytokine blockade or modulation
[53,54], and epithelial cell protection or regeneration
(KGF-1 and HGF) [36,37,55,56]. These studies have
provided considerable insight into the role the GI
tract plays in GVHD and may ultimately lead to novel
approaches to separate the toxicity of GVHD from
the beneﬁts of GVL activity in the clinical setting.
The precise mechanism of mucosal barrier func-
tional homeostasis as facilitated by repifermin remains
to be determined. Several models of murine epithelial
cell injury have demonstrated the effectiveness of us-
ing KGFs to speed healing, reduce mucosal damage,
and facilitate epithelial cell recovery [29,32,50,57].
KGF-1 has cytoprotective effects in models of muco-
sal proliferation [58] and injury [46,48,49] and in ir-
radiated murine BMT models [36,41,42,59,60]. In
particular, previous work from this laboratory has
demonstrated that KGF-1 reduces GVHD and pre-
serves GVL [41]. Repifermin’s lack of modulation on
donor T-cell responses and CTL function are consis-
tent with that study. These ﬁndings, however, contrast
with observations from a different murine BMT
model [36], which likely reﬂects the different condi-
tioning regimens used in these studies.
Although repifermin and KGF-1 share some im-
portant similarities [61] and might be expected to
protect epithelium in a similar manner, they also differ
in several important respects. The primary structure
of repifermin is only 57% homologous to that of
KGF-1 [29]. Both proteins bind to the KGF receptor,
FGFR2iiib (located exclusively on epithelial cells
[41,56,58] and ubiquitously expressed throughout the
gut epithelium [62]), but the binding afﬁnity for this
receptor is 10-fold higher for KGF-1 than for repi-
fermin [32]. In addition, only repifermin binds to a
second epithelial-speciﬁc receptor, FGFR1iiib. These
observations likely explain why both KGFs are capa-
ble of stimulating dermal epithelial cell division,
whereas repifermin causes more epithelial cell migra-
tion [10]. Enhanced cellular migration into the dam-
aged epithelium of the intestinal tract may be impor-
tant to prevent the transport of endotoxin into the
systemic circulation, thereby downregulating the in-
ﬂammatory cytokine cascade characteristic of GVHD.
The reduced intestinal damage caused by GVHD af-
ter repifermin treatment is consistent with this notion
and with its effectiveness in other models of intestinal
injury [63,64].
Repifermin can prevent GVHD after several in-
tensities of conditioning regimens, because prelimi-
nary experiments that used 1100 and 1300 cGy of TBI
repifermin exhibited protective effects similar to those
observed after 1500 cGy (data not shown). These data
are thus very similar to those published for KGF-1
and GVHD. The subtle differences in survival proﬁles
for repifermin-treated mice compared with previously
published results for KGF-1 may be due to the differ-
ential receptor afﬁnities of these 2 molecules.
KGFs are known to be internalized by receptor-
mediated endocytosis involving clathrin-coated pits
[65], whereby receptor-ligand complexes accumulate
within cells, resulting in slower degradation kinetics.
This mechanism may explain why the therapeutic
beneﬁt of KGFs after radiation-induced damage can
persist after cessation of drug delivery. It should be
noted, however, that our results do not demonstrate a
Figure 5. Repifermin preserves an allogeneic GVL effect. B6D2F1
recipient mice were conditioned and underwent transplantation as
described in Figure 1. A total of 2000 P815 (H-2d) tumor cells were
added to the bone marrow inoculum on day 0. Mice received either
TCD bone marrow (solid symbols) or bone marrow plus T cells and
injections of diluent (circles) or repifermin (squares) as indicated
with the black bar along the x axis. Results are represented by
Kaplan-Meier cumulative survival curve estimates combining 2 sim-
ilar experiments (F allogeneic TCD, n 
8; f allogeneic TCD 
repifermin, n
12; E allogeneic, n
27; allogeneic repifermin,
n 
20,  versus E, P 
 .04).
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signiﬁcantly improved beneﬁt in terms of survival or
clinical score through continuance of repifermin ther-
apy long after BMT. We observed similar clinical
score proﬁles for mice treated with higher doses of
repifermin (10 and 20 mg/kg), as well as those given
longer administration courses. These ﬁndings are
consistent with recent studies [37,66] that also did not
observe enhanced survival when additional KGF-1 (5
mg/kg) was administered. The loss of protection ob-
served early for both KGF-1 and repifermin, coupled
with the ineffectiveness of longer schedules of repifer-
min, suggests that these agents may be most effective
at preventing the early acute GVHD damage associ-
ated with the inﬂammation of the conditioning regi-
men and may be less effective at preventing more
chronic sequelae mediated by the ongoing activities of
cellular effectors.
In experiments using P815 (MHC I/MHC II)
target cells, GVL activity is mediated by CD8 and
CD4 T cells; CD4 cells are necessary for activation
and expansion of CD8 effectors and TNF genera-
tion [5,41,46]. Neither T-cell subset was appreciably
altered in number in the spleen after BMT, and CTL
function was not altered by repifermin administration.
Notably, all mice that received T cells and repifermin
survived to day 21 in our GVL experiments, although
much of this survival advantage was gradually lost
during subsequent weeks. GVHD was the most likely
cause of these late deaths, as evidenced by the lack of
observable tumor cells in target tissues by histology
and/or FACS analysis, as well as increased GVHD
clinical scores and pronounced splenic atrophy. This
late mortality may be due to a persistent GVH reac-
tion directed against host target tissues that is ampli-
ﬁed by the presence of P815 alloantigens and that
continued after the protective effects of the therapeu-
tic treatment had diminished. Alternatively, because
this phenomenon was not as pronounced in previous
studies that used KGF-1, it may be related to the
lower binding efﬁciency of the FGFR2iiib receptor
for repifermin, which could lead to reduced mucosal
proliferation in the context of systemic leukemia. This
interpretation would not require differential expres-
sion of FGFR1iiib and FGFR2iiib in the gut epithe-
lium or altered receptor expression during leukemia
progression [62]. However, we believe the most likely
explanation for the diminished survival after tumor
inoculation is the increased host alloantigen available
to stimulate donor T cells after BMT, consistent with
the reduced survival that is commonly observed in
other GVL models [5,41,46].
Repifermin (KGF-2) joins a growing list of epi-
thelial growth factors (including EGF, HGF, TGF,
and KGF-1) [36,39,55,56,67] with radioprotective, cy-
toprotective, and/or shielding effects thought to have
therapeutic potential for treating GVHD. If repifer-
min acts in a similar fashion to EGF [68], mucosal
regeneration may occur via upregulation of IL-7R
expression on intestinal epithelial cells, which are pro-
tected by IL-7 [39], although this mechanism remains
to be demonstrated. BMT strategies increasingly rely
on the immunotherapeutic potential of allogeneic do-
nor cells, and, thus, additional approaches to prevent
GVHD that do not suppress donor cell function are
potentially advantageous. The GI tract is an important
site for multiple interactions relevant to the patho-
physiology of GVHD, and, thus, options that enhance
mucosal integrity either directly (as with repifermin)
or indirectly (as with TNF-blocking agents such as
etanercept) warrant further study.
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